Updates are available Correction dated 2023-02-13
Click to view Correction: https://doi.org/10.1186/s40359-023-01083-9
-
Authors
Badaghi, Nasim http://orcid.org/0000-0002-7529-3448
van Kruijsbergen, Mette
Prins, Judith
Kelders, Saskia
Cillessen, Linda
Compen, Félix
Donders, Rogier
Kwakkenbos, Linda
Speckens, Anne
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (12125)
- License Information
-
More Information
Article History
Received: 22 December 2022
Accepted: 13 January 2023
First Online: 25 January 2023
Change Date: 15 February 2023
Change Type: Update
Change Details: This article has been corrected since original publication; please see the linked erratum for futher details.
Change Date: 13 February 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1186/s40359-023-01083-9
Declarations
:
: The Buddy Trial has been approved by the ethical review board, CMO Arnhem-Nijmegen (number: NL73117.091.20). The study will be conducted according to the principles of the Declaration of Helsinki (6th edition, 2008) and in accordance with the Medical Research Involving Human Subjects Act (WMO). Participation is free of charge and voluntary (participate patients must sign the informed consent). We believe that the risks of participation are negligible. However, we will monitor for potential adverse reactions. Participants can contact the researchers during the intervention period when necessary. Any significant modifications made to the protocol will be submitted as an amendment to the medical ethics committee and documented in the trial’s registration.
: Not applicable.
: The authors declare they have no known competing financial interests or relationships that could influence the work in this manuscript.
